A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Apr 2017 Planned End Date changed from 1 Sep 2015 to 1 Dec 2017.
- 05 Apr 2017 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2017.
- 09 Feb 2015 Planned End Date changed from 1 Jul 2014 to 1 Sep 2015 according to ClinicalTrials.gov record.